Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.
Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Matsui Y, Kon M. Karabicak I, et al. Among authors: kon m. J Hepatobiliary Pancreat Sci. 2016 Dec;23(12):750-755. doi: 10.1002/jhbp.408. Epub 2016 Nov 22. J Hepatobiliary Pancreat Sci. 2016. PMID: 27794194
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, Yamada S, Yamamoto T, Mizuma M, Honda G, Isayama H, Unno M, Kodera Y, Ishigami H, Kon M. Satoi S, et al. Among authors: kon m. Ann Surg. 2017 Feb;265(2):397-401. doi: 10.1097/SLA.0000000000001705. Ann Surg. 2017. PMID: 28059968 Free article. Clinical Trial.
Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution.
Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Hashimoto Y, Matsui Y, Kon M. Satoi S, et al. Among authors: kon m. J Hepatobiliary Pancreat Sci. 2017 May;24(5):289-296. doi: 10.1002/jhbp.447. Epub 2017 Apr 19. J Hepatobiliary Pancreat Sci. 2017. PMID: 28301088
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Kinoshita S, Nishiwada S, Nagai M, Ikeda N, Tsuta K, Nakajima Y, Kon M. Yanagimoto H, et al. Among authors: kon m. Cancer Chemother Pharmacol. 2016 Jan;77(1):35-41. doi: 10.1007/s00280-015-2928-z. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645403 Clinical Trial.
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M. Yanagimoto H, et al. Among authors: kon m. Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4. Nutr Cancer. 2016. PMID: 26847832 Clinical Trial.
552 results